Stem Cell Educator Therapy in Alopecia Areata

This study is currently recruiting participants.
Verified August 2012 by Tianhe Stem Cell Biotechnologies Inc.
Sponsor:
Collaborator:
Hebei Medical University First Hospital
Information provided by (Responsible Party):
Tianhe Stem Cell Biotechnologies Inc.
ClinicalTrials.gov Identifier:
NCT01673789
First received: August 21, 2012
Last updated: August 23, 2012
Last verified: August 2012
  Purpose

Alopecia Areata (AA) is one of the most common T cell-mediated autoimmune diseases, leading to the chronic and relapsing hair loss. The prevalence of AA worldwide is 0.1 to 0.2%, affecting an estimated 5.3 million people in the United States. To date, the clinical therapies are limited and disappointed for the treatment of AA. Alternative approaches are needed. Increasing evidence demonstrates that stem cells possess the function of immune modulation. We established the Stem Cell Educator therapy by using cord blood-derived multipotent stem cells (CB-SCs)(Zhao Y, et al. BMC Medicine 2012). A closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with adherent CB-SCs in vitro, and returns the educated lymphocytes (but not the CB-SCs) to the patient's circulation. Our clinical trial reveals that a single treatment with the Stem Cell Educator provides lasting reversal of autoimmunity that allows regeneration of islet beta cells and improvement of metabolic control in subjects with long-standing type 1 diabetes (T1D), which is another most common T cell-mediated autoimmune disorder in the United States. Here, we develop and explore the therapeutic effectiveness of Stem Cell Educator therapy in AA patients.


Condition Intervention Phase
Alopecia Areata
Device: Stem Cell Educator
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1/Phase 2 Study of Stem Cell Educator Therapy in Alopecia Areata

Further study details as provided by Tianhe Stem Cell Biotechnologies Inc.:

Primary Outcome Measures:
  • Feasibility and efficacy of Stem Cell Educator therapy in AA [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    The primary study end points are 1) feasibility of the Stem Cell Educator therapy in AA, 2) preliminary evaluation of the efficacy of the therapy for improving hire grow through a year.


Secondary Outcome Measures:
  • The efficacy of Stem Cell Educator therapy in modulating autoimmunity [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The secondary study end point was evidence of the efficacy of the therapy in modulating autoimmunity. Baseline blood samples are collected prior to Stem Cell Educator therapy.


Estimated Enrollment: 30
Study Start Date: August 2012
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stem Cell Educator
The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
Device: Stem Cell Educator
For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.

Detailed Description:

A 16-gauge IV needle is placed in the left (or right) median cubital vein, and the patient's blood is passed through a Blood Cell Separator MCS+ (Haemonetics®, Braintree, MA) at 35 mL/min for 6 to 7 hours to isolate lymphocytes in accordance with the manufacturer's recommended protocol. The collected lymphocytes are transferred into the device for exposure to allogeneic CB-SCs (or process control without CB-SCs), and other blood components are returned to the patient. After 2 to 3 hours in the device, lymphocytes are returned to the patient's circulation via a dorsal vein in the hand under gravity flow control (2 to 3 mL/min) with physiological saline. Approximately 10,000 mL of blood is processed during the procedure resulting in approximately two repeated educations for the lymphocyte fraction. Patients are hospitalized for two days to monitor temperature and conduct routine laboratory blood tests for adverse reactions following treatment. Follow-up visits are scheduled 4, 12, 24, 40, and 54 weeks after treatment for clinical assessments and laboratory tests

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients are screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards recommended by the National Alopecia Areata Foundation (www.naaf.org).

Exclusion Criteria:

  • Exclusion criteria are any clinically significant diseases in liver, kidney, and heart. Additional exclusion criteria are no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01673789

Locations
China, Hebei
The First Hospital of Hebei Medical University Recruiting
Shijiazhuang, Hebei, China, 050031
Contact: Yanjia Li, MD    86 311 85917311    liyanjia2008@gmail.com   
Sub-Investigator: Yanjia Li, MD         
Sponsors and Collaborators
Tianhe Stem Cell Biotechnologies Inc.
Hebei Medical University First Hospital
Investigators
Study Chair: Yong Zhao, MD, PhD Tianhe Stem Cell Biotechnologies Inc.
  More Information

Additional Information:
Publications:
Responsible Party: Tianhe Stem Cell Biotechnologies Inc.
ClinicalTrials.gov Identifier: NCT01673789     History of Changes
Other Study ID Numbers: 2012-TH01
Study First Received: August 21, 2012
Last Updated: August 23, 2012
Health Authority: China: Ethics Committee
China: Food and Drug Administration

Keywords provided by Tianhe Stem Cell Biotechnologies Inc.:
Stem Cell Educator
Cord blood stem cells
Immune modulation
Alopecia Areata

Additional relevant MeSH terms:
Alopecia
Alopecia Areata
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on April 22, 2014